Hyperion Therapeutics Inc. broadened its orphan disease pipeline in a big way by inking an agreement to acquire Andromeda Biotech Ltd., an Israel-based subsidiary of Clal Biotechnology Industries Ltd., in a carefully crafted deal that links much of the economics to back-end milestones.